About

 

Company Overview

Quantitative Medicine is an early stage computational biology company based out of Revv Oakland in Pittsburgh, Pennsylvania. The company is commercializing an advanced, big data analytics technology – the Computational Research Engine™ (CoRE™) – that facilitates accelerated drug discovery and development while dramatically lowering experimentation costs.

Professor Robert F. Murphy PhD and Joshua Kangas PhD, two of Quantitative Medicine’s founders, developed and patented the active machine learning technology used in CoRE™ at the Ray and Stephanie Lane Center for Computational Biology at Carnegie Mellon University. The company is now licensing this breakthrough innovation in big data analytics.

Quantitative Medicine’s Computational Research Engine™ uses an innovative approach to machine learning in drug discovery and development that complements and extends current industry practices. The CoRE™ does not replace experimentation with computation, it simply shares the stage. The company is unique in its collaborative approach, employing computation to guide physical experimentation. The unprecedented benefits resulting from the synergistic partnership between the CoRE™‘s active machine learning technology and the scientists who utilize it are without equal. Quantitative Medicine’s drive to innovate and willingness to rewrite tired convention will not be found anywhere else.

What is CoRE™
CoRE™ Services

Leadership

Board of Directors

Management

img_JoshKangas_160x210

Joshua D Kangas, PhD – Founder and Chief Executive Officer
Josh has worked on a number of projects that applied machine learning to molecular biology, genomics, image analysis and biological literature mining. The most significant work has been the application of active learning techniques for drug discovery which led to the development and patenting of the active learning CoRE™. Josh holds a PhD in Computational Biology from Carnegie Mellon University.
mailiconlinkedinicon


Board of Directors

Scott R Bodine – Founder and Chairman of the Board
Scott has extensive experience in enterprise systems design and deployment in the financial services industry and in design of quantitative financial analytics. In executive management and sales roles, he directly managed $500M of client capital deployment at firms including Credit Suisse, Deutsche Bank, Barclay’s Capital, General Electric and Sun Microsystems. Scott holds BS degrees in both Electrical and Computer Engineering and in Applied Mathematics/Computer Science from Carnegie Mellon University.
mailiconlinkedinicon


img_RobertMurphy_160x210

Robert F Murphy, PhD – Founder and Director
Dr. Murphy has been a pioneer in the use of machine learning methods for the analysis high-resolution fluorescence microscopy images. He co-developed the CoRE™ with Josh Kangas and colleagues at Carnegie Mellon University. He is the Ray and Stephanie Lane Professor and Director (Department Head) of the Ray and Stephanie Lane Center for Computational Biology in the School of Computer Science at Carnegie Mellon University. He is also Professor of Biological Sciences, Biomedical Engineering and Machine Learning. Dr. Murphy holds a PhD in Biological Sciences from the California Institute of Technology.
linkedinicon


img_MarcVerez

Marc Verez – Director
Marc pent 30 years at FedEx handling multiple sales leadership responsibilities. The last 15 years he was the Managing Director of Worldwide sales responsible for over $450,000,000 in revenue.
linkedinicon


img_JoshKangas_160x210

Joshua D Kangas, PhD – Founder and Chief Executive Officer
Josh has worked on a number of projects that applied machine learning to molecular biology, genomics, image analysis and biological literature mining. The most significant work has been the application of active learning techniques for drug discovery which led to the development and patenting of the active learning CoRE™. Josh holds a PhD in Computational Biology from Carnegie Mellon University.
mailiconlinkedinicon


Back to Top
Enter your Infotext or Widgets here...